TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies

Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and...

Descripción completa

Detalles Bibliográficos
Autores principales: Carideo Cunniff, Elizabeth, Sato, Yosuke, Mai, Doanh, Appleman, Vicky A., Iwasaki, Shinji, Kolev, Vihren, Matsuda, Atsushi, Shi, Judy, Mochizuki, Michiyo, Yoshikawa, Masato, Huang, Jian, Shen, Luhua, Haridas, Satyajeet, Shinde, Vaishali, Gemski, Chris, Roberts, Emily R., Ghasemi, Omid, Bazzazi, Hojjat, Menon, Saurabh, Traore, Tary, Shi, Pu, Thelen, Tennille D., Conlon, Joseph, Abu-Yousif, Adnan O., Arendt, Christopher, Shaw, Michael H., Okaniwa, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010323/
https://www.ncbi.nlm.nih.gov/pubmed/36923556
http://dx.doi.org/10.1158/2767-9764.CRC-21-0161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010323/
https://www.ncbi.nlm.nih.gov/pubmed/36923556
http://dx.doi.org/10.1158/2767-9764.CRC-21-0161

Ejemplares similares